The role of FOLFIRINOX in metastatic pancreatic cancer: a meta-analysis

The role of FOLFIRINOX in metastatic pancreatic cancer: a meta-analysis

Background The prognosis of pancreatic cancer (PC) is extremely poor, and most patients with metastatic PC still receive palliative care. Here, we report the efficacy and safety of FOLFIRINOX (oxaliplatin, irinotecan, leucovorin, 5-fluorouracil) in the treatment of metastatic PC. Methods We searched...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:World journal of surgical oncology 2021-06, Vol.19 (1), p.1-182, Article 182
Hauptverfasser: Zhang, Beilei, Zhou, Fengyan, Hong, Jiaze, Ng, Derry Minyao, Yang, Tong, Zhou, Xinyu, Jin, Jieyin, Zhou, Feifei, Chen, Ping, Xu, Yunbao
Format: Artikel
Sprache:eng
Schlagworte:
5-Fluorouracil
Adverse events
Bias
Cancer
Cancer therapies
Care and treatment
Chemotherapy
Collaboration
Complications and side effects
Diagnosis
Diarrhea
Drug therapy, Combination
Efficacy
FOLFIRINOX
Gastrointestinal system
Gemcitabine
Irinotecan
Leukocytes
Medical prognosis
Meta-analysis
Metastases
Metastasis
Metastatic pancreatic cancer
Neutropenia
Oxaliplatin
Paclitaxel
Pancreatic cancer
Patient outcomes
Patients
Prognosis
Review
Safety
Sensitivity analysis
Subgroups
Survival
Toxicity
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background The prognosis of pancreatic cancer (PC) is extremely poor, and most patients with metastatic PC still receive palliative care. Here, we report the efficacy and safety of FOLFIRINOX (oxaliplatin, irinotecan, leucovorin, 5-fluorouracil) in the treatment of metastatic PC. Methods We searched PubMed, Web of Science, EBSCO, and Cochrane library databases for articles that described efficacy and safety of FOLFIRINOX in patients with metastatic PC, from January 1996 to July 2020. The primary outcomes targeted included overall survival (OS) and progression-free survival (PFS). Results We found that FOLFIRINOX could directly improve OS rate of patients with metastatic PC (HR 0.76, 95% Cl 0.67-0.86, p
ISSN:1477-7819
1477-7819
DOI:10.1186/s12957-021-02291-6